How Analysts Feel About Rosetta Genomics Ltd. (ROSG) After Forming Multiple Bottom Pattern?

May 16, 2018 - By Alfred Lee

Rosetta Genomics Ltd. (NASDAQ:ROSG) Logo

The stock of Rosetta Genomics Ltd. (ROSG) shows a multiple bottoms pattern with $0.39 target or 8.00 % below today’s $0.42 share price. The 8 months chart pattern indicates high risk for the $2.51 million company. It was reported on May, 16 by Finviz.com. If the $0.39 price target is reached, the company will be worth $200,720 less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 3.84% or $0.0169 during the last trading session, reaching $0.4231. About 62,851 shares traded. Rosetta Genomics Ltd. (NASDAQ:ROSG) has declined 87.46% since May 16, 2017 and is downtrending. It has underperformed by 99.01% the S&P500.

Another recent and important Rosetta Genomics Ltd. (NASDAQ:ROSG) news was published by Streetinsider.com which published an article titled: “Rosetta Genomics (ROSG) Announces Shareholder Approval of Merger with Genoptix” on April 26, 2018.

Rosetta Genomics Ltd. operates as a genomic diagnostics firm worldwide. The company has market cap of $2.51 million. The companyÂ’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It currently has negative earnings. It also provides UroVysion, a urine Fluorescence In Situ Hybridization assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH prognostic tests in prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: